文献速递垂体与肾上腺疾病

肾上腺皮质功能不全中的组织糖皮质激素代谢:双释放氢化可的松治疗的前瞻性研究

Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

前瞻性交叉研究纳入51例原发性与继发性肾上腺皮质功能不全患者,比较双释放氢化可的松(DR-HC)与即释氢化可的松(IR-HC)对全身及组织糖皮质激素代谢的影响。结果发现IR-HC治疗者尿皮质醇排泄高于健康对照,且11β-HSD2活性降低、5α-还原酶活性升高;换用DR-HC后尿皮质醇及总GC代谢物排泄显著减少,11β-HSD2活性升高,皮下脂肪组织11β-HSD1表达与活性显著降低,而肝脏11β-HSD1活性无显著改变。

要点

  • 接受IR-HC的肾上腺皮质功能不全患者24小时尿皮质醇排泄中位数高于健康对照。
  • 换用DR-HC后尿皮质醇与总GC代谢物排泄显著减少,以夜间最明显。
  • 换用DR-HC后皮下脂肪组织11β-HSD1表达与活性显著降低。

核心结论

  • 使用全面的体内技术,本研究发现接受IR-HC的原发性和继发性肾上腺皮质功能不全患者存在皮质类固醇代谢异常。
  • 这种前受体糖皮质激素代谢失调导致脂肪组织中糖皮质激素激活增强,而DR-HC治疗可改善这一异常。

研究设计与样本

  • 前瞻性交叉研究,评估12周DR-HC对51例原发性和继发性肾上腺皮质功能不全患者全身GC代谢、肝脏皮质醇激活及皮下脂肪组织的影响。
  • 对照包括IR-HC治疗和年龄及BMI匹配的健康对照。

主要发现

  • 接受IR-HC的肾上腺皮质功能不全患者24小时尿皮质醇排泄中位数高于健康对照:72.1 µg/24小时(IQR 43.6-124.2)vs 51.9 µg/24小时(IQR 35.5-72.3),P = .02。
  • IR-HC治疗者整体11β-HSD2活性较低、5α-还原酶活性较高。
  • 从IR-HC换用DR-HC后,尿皮质醇和总GC代谢物排泄显著减少,夜间最显著。
  • 换用DR-HC后11β-HSD2活性升高;肝脏11β-HSD1活性无显著改变,但皮下脂肪组织11β-HSD1表达和活性显著降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with adrenal insufficiency (AI) require life-long glucocorticoid (GC) replacement therapy. Within tissues, cortisol (F) availability is under the control of the isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD). We hypothesize that corticosteroid metabolism is altered in patients with AI because of the nonphysiological pattern of current immediate release hydrocortisone (IR-HC) replacement therapy. The use of a once-daily dual-release hydrocortisone (DR-HC) preparation, (Plenadren®), offers a more physiological cortisol profile and may alter corticosteroid metabolism in vivo. STUDY DESIGN AND METHODS: Prospective crossover study assessing the impact of 12 weeks of DR-HC on systemic GC metabolism (urinary steroid metabolome profiling), cortisol activation in the liver (cortisone acetate challenge test), and subcutaneous adipose tissue (microdialysis, biopsy for gene expression analysis) in 51 patients with AI (primary and secondary) in comparison to IR-HC treatment and age- and BMI-matched controls. RESULTS: Patients with AI receiving IR-HC had a higher median 24-hour urinary excretion of cortisol compared with healthy controls (72.1 µg/24 hours [IQR 43.6-124.2] vs 51.9 µg/24 hours [35.5-72.3], P = .02), with lower global activity of 11β-HSD2 and higher 5-alpha reductase activity. Following the switch from IR-HC to DR-HC therapy, there was a significant reduction in urinary cortisol and total GC metabolite excretion, which was most significant in the evening. There was an increase in 11β-HSD2 activity. Hepatic 11β-HSD1 activity was not significantly altered after switching to DR-HC, but there was a significant reduction in the expression and activity of 11β-HSD1 in subcutaneous adipose tissue. CONCLUSION: Using comprehensive in vivo techniques, we have demonstrated abnormalities in corticosteroid metabolism in patients with primary and secondary AI receiving IR-HC. This dysregulation of pre-receptor glucocorticoid metabolism results in enhanced glucocorticoid activation in adipose tissue, which was ameliorated by treatment with DR-HC.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dineen RA, Martin-Grace J, Ahmed KMS, et al. Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy. J Clin Endocrinol Metab. 2023. PMID: 37339332. doi:10.1210/clinem/dgad370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。